Ultragenyx Converts Two Rare Disease Approvals Into $413 Million in Voucher Sales
Ultragenyx Pharmaceutical has turned two recent gene therapy approvals into a major cash infusion, selling both priority review vouchers for a combined $413 million. The deals arrive at a pivotal financial moment for the Novato, California-based rare disease company, which is now looking to shore up its pipeline after a costly Phase 3 failure in Angelman syndrome.
The first voucher sale was priced at $210 million, followed a week later by a second agreement worth $203 million. Both buyers remain undisclosed, and the transactions still have to satisfy closing conditions. Even so, the structure is straightforward: Ultragenyx is converting regulatory assets into non-dilutive capital, a move that can support business development without adding shareholder dilution or debt pressure.
For a company built around ultra-rare disorders, that matters immediately. Drug development in this space is expensive, the patient populations are small, and the commercial ceiling on first-in-class therapies is often limited even when the science is strong. A voucher sale can provide a practical financing bridge between regulatory success and the next acquisition or in-licensing opportunity.
Two Gene Therapy Approvals, Two Fast-Track Assets
The vouchers came from two separate FDA approvals granted within a month of each other. One was attached to Gengylcos, a gene therapy approved in late August for glycogen storage disease type Ia, a rare inherited enzyme deficiency. The other came with the mid-September approval of Fayuvi, a gene therapy for Sanfilippo syndrome type A, another inherited enzyme deficiency and the first approved therapy for that indication.
Each approval carried more than medical significance. Under the rare pediatric disease priority review voucher program, an approved company can receive a transferable voucher that shortens the FDA’s standard review timeline from 10 months to six months. The voucher is valuable because speed itself has strategic worth in drug development: a six-month review can accelerate a launch, improve competitive positioning, and compress the time between investment and regulatory answer.
Congress created the program to encourage drug development for rare pediatric diseases, where market incentives are weak and scientific risk is high. In practice, the vouchers have become tradable assets, often sold to larger pharmaceutical companies that want a faster regulatory path for their own products. Recent demand has pushed prices upward, and most vouchers sold this year have brought in $200 million or more.
The pricing in Ultragenyx’s deals fits that market pattern.
Cash Without Dilution After a Painful Pipeline Setback
The timing of the sales is especially important because Ultragenyx has been absorbing another kind of regulatory and clinical pressure. Last month, the company disclosed that apazunersen, its antisense oligonucleotide therapy for Angelman syndrome, missed its Phase 3 endpoint. The failure was more than a single program setback; it prompted management to move toward corporate restructuring and expense reductions.
Angelman syndrome had been a central commercial and strategic bet for Ultragenyx. The drug was not internally discovered but came through an acquisition, and the program had been among the company’s most visible future growth drivers. When that trial failed, the company lost not just a late-stage asset but a key narrative around long-term value creation in a pipeline dominated by rare disease programs.
Against that backdrop, the voucher monetization looks less like opportunistic asset sales and more like balance-sheet triage. Ultragenyx said it intended to sell both vouchers, and the proceeds now give the company a stronger financial cushion as it considers what comes next in rare disease business development.
The company has not disclosed how the money will be deployed. It had $436 million in cash at the end of June, and it is due to report third-quarter 2026 financial results in November. Those disclosures should give a clearer picture of how far the company can stretch its capital base while still pursuing another rare disease transaction.
Rare Disease Economics Favor Regulatory Assets as Much as Drugs
Ultragenyx’s experience shows how rare disease companies increasingly extract value not only from approved therapies but from the regulatory milestones attached to them. The biology may determine whether a product is approvable, yet the business model often depends on converting approval into a second asset with immediate market value. In this case, the therapy itself may not be a major revenue engine, but the voucher it generated became a meaningful source of capital.
The company has used this model before. Ultragenyx previously received vouchers tied to rare disease approvals in 2017 and 2018, and Chief Financial Officer Howard Horn said in a prepared statement that the Sanfilippo therapy benefited from capital generated by an earlier voucher sale. His comment framed the program as a recurring financial tool rather than a one-time windfall, “demonstrating the important role the priority review voucher program plays in helping companies develop impactful therapies for rare disease patients.”
That logic is especially relevant when approved products address ultra-small populations. Even a first-in-class therapy may not generate enough revenue to carry a broad portfolio by itself, particularly if development costs have been high and launch populations are tiny. A voucher sale can help bridge that gap and support the next round of scientific risk-taking.
Investors Are Watching the Next Use of Capital, Not Just the Sale
William Blair analyst Lachlan Hanbury-Brown said in a Wednesday research note that Ultragenyx still lacks clinical catalysts over the next year that would likely drive stock value, despite the launch of two gene therapies. His view places the emphasis squarely on pipeline execution and capital allocation rather than on the voucher windfall alone.
The sale does strengthen the balance sheet with non-dilutive capital, but investors will want a concrete answer to a narrower set of questions: how the company will deploy the proceeds, how quickly it can cut expenses, and whether management can translate those actions into a path toward generally accepted accounting principles profitability in 2027. Hanbury-Brown said he looks forward to management’s plans for the additional capital and the company’s expense reductions.
For now, the vouchers offer Ultragenyx both breathing room and leverage. The company has turned two rare pediatric approvals into cash at a moment when one of its most important development programs has failed, and the next move will likely determine whether the business uses that room to rebuild around another rare disease asset or simply to stabilize after a difficult year.